Aficamten

Aficamten, Cytokinetics' cardiac myosin inhibitor, met its primary endpoint in the Phase 3 MAPLE-HCM trial, demonstrating significant improvement in peak oxygen uptake in obstructive hypertrophic cardiomyopathy patients.

Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls.

Cytokinetics will present five studies on aficamten at the upcoming ACC Scientific Session, including new data on its metabolism pathways through multiple CYP enzymes and the safety of combination therapy with disopyramide.

Cytokinetics has commenced enrollment for the AMBER-HFpEF Phase 2 trial to assess CK-586 in patients with symptomatic heart failure with preserved ejection fraction (HFpEF).

Cytokinetics stopped the Phase 3 COURAGE-ALS trial of resedemtiv for amyotrophic lateral sclerosis (ALS) after a futility analysis showed no benefit over placebo.